CONTACT
Group Companies
MEDIA STORIES
 20-Sep-2021
Biocon Biologics, Serum Institute Life Sciences announce strategic alliance
 20-Sep-2021
Biocon jumps into vaccines through $4.9bn Serum Institute pact
 20-Sep-2021
Can Serum deal provide a booster dose to Biocon’s target price?
 20-Sep-2021
Interchangeable insulin to help us compete with big insulin makers: Kiran Mazumdar-Shaw
 29-Aug-2021
Vaccines alone will not protect and make the world safer: Biocon chief
 30-Jul-2021
India must use, share Covid data transparently: Kiran Mazumdar-Shaw
 26-Jul-2021
Biocon partners Adagio for licence to make Covid-19 antibody cocktail
 26-Jul-2021
Biocon eyes market share expansion in developed, emerging markets: Kiran Mazumdar-Shaw
 23-Jul-2021
Biocon Q4 profit more than doubles to Rs 254 crore
 29-Apr-2021
Shreehas Tambe named Deputy CEO of Biocon Biologics
 02-Mar-2021
Biocon Biologics, Viatris get CHMP nod for Abevmy
 02-Mar-2021
Biocon Biologics to partner with International Diabetes Federation
 16-Feb-2021
Biocon arm, CHAI in pact on affordable cancer therapies
 04-Feb-2021
Expect Accelerated Growth from Next Fiscal, Says Kiran Mazumdar-Shaw
 25-Jan-2021
Biocon says may have to delay biologics biz IPO
 25-Jan-2020
PANDEMIC PAIN Biocon Chairperson Kiran Mazumdar-Shaw says the Covid impact on business across the value chain has been larger than expected p2
 25-Jan-2020
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs
08-Nov-2020
India-based company brings affordable insulin to 2 PH towns
23-Oct-2020
Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?
 01-Aug-2020
India’s Biocon secures approval to use drug on coronavirus patients
 11-July-2020
Biosimilar drugs can help us reach $1 billion target soon
16-Jun-2020
Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020
 06-Jun-2020
Covid provides larger opportunity to shape the biosimilar landscape
 19-May-2020
Will invest Rs2,000 crore in small molecules in 3-4 years
 16-May-2020
Biocon wins patent case against Sanofi
 12-Mar-2020
Biocon’s cancer biosimilar gets US FDA acceptance for review
 10-Mar-2020
Biocon chief is EY entrepreneur for 2019
 22-Feb-2020
Biocon Biologics Eyes $200M. Plans IPO in 2 Yrs: Mazumdar-Shaw
 27-Jan-2020
Biocon Q3 PBT up 9%
 24-Jan-2020
Biocon optimistic about hitting $1 billion in revenue by FY22 on back of new launches
 08-Jan-2020
Biocon, partner Mylan launch oncology biosimilar trastuzumab in US
11-Dec-2019
USFDA nod to Biocon’s new Bengaluru unit
28-Nov-2019
Biocon, Mylan get nod for pegfilgrastim drug
28-Nov-2019